Matthew Carraro, MD
Neurology · Charlotte, NCNPI 1437441052
Payments from drug & device makers
Across 850 payments — averaging $1759.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$480K
- Novartis$343K
- TG Therapeutics, Inc.$298K
- EMD Serono, Inc.$238K
- Biogen$95K
- Genentech USA, Inc.$29K
- plus $12K from 29 others
Across 14 payments — averaging $245.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$3K
What the payments were for
- Consulting fees$115,88117%
- Speaking & faculty fees$513,83274%
- Travel & lodging$50,3137%
- Food & beverage$14,2782%
- Education$2090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 180 | $480,260 |
| Novartis | 36 | $342,745 |
| TG Therapeutics, Inc. | 144 | $298,278 |
| EMD Serono, Inc. | 202 | $238,211 |
| Biogen | 96 | $94,504 |
| Genentech USA, Inc. | 34 | $29,419 |
| Amgen(2 entities) | 11 | $4,760 |
| Genentech, Inc. | 3 | $1,896 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,750 |
| Janssen Scientific Affairs, LLC | 1 | $1,320 |
| AbbVie | 23 | $475 |
| Pfizer | 22 | $436 |
| Acadia Pharmaceuticals Inc | 29 | $369 |
| AstraZeneca | 14 | $300 |
| Bristol Myers Squibb | 10 | $220 |
| Teva Pharmaceuticals USA, Inc. | 9 | $180 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $126 |
| Lundbeck LLC | 5 | $108 |
| MDD US Operations, LLC | 4 | $82 |
| Lilly USA, LLC | 3 | $45 |
| Sunovion Pharmaceuticals Inc. | 2 | $40 |
| Medtronic(2 entities) | 2 | $35 |
| Octapharma USA, Inc. | 2 | $33 |
| Grifols USA, LLC | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Abbott | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Eisai Inc. | 1 | $22 |
| Banner Life Sciences, LLC | 1 | $21 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,495,846 in reported general payments places this provider in the 95th percentile of 566 neurology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 105 | $1,022,620 |
| AmpyraDalfampridine | 11 | $45,883 |
| Dalfampridine ErDalfampridine | 74 | $29,613 |
| Nurtec OdtRimegepant Sulfate | 18 | $28,121 |
| Dimethyl Fumarate | 11 | $26,070 |
| Aimovig AutoinjectorErenumab-Aooe | 17 | $15,486 |
| Gabapentin | 67 | $2,549 |
| Baclofen | 95 | $1,772 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 48 | $1,332 |
| Pregabalin | 30 | $1,318 |
| Oxcarbazepine | 17 | $1,287 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 24 | $1,130 |
| Lacosamide | 12 | $912 |
| Propranolol Hcl ErPropranolol Hcl | 18 | $705 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $436 | $28,12118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 566 neurology providers in North Carolina.
Other neurology in Charlotte
- Mohammad BolouriCharlotte$16.6M
- T RaoCharlotte$4M
- Donna GravesCharlotte$1.8M
- Jill ConwayCharlotte$1.6M
- Urvi DesaiCharlotte$937K
- Ardith CourtneyCharlotte$862K
- Sanjay IyerCharlotte$685K
- Megan DonnellyCharlotte$601K
- Kenneth AshkinCharlotte$525K
- Leo McCluskeyCharlotte$286K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.